DC MPJE - independent pharmacy jurisprudence foundations flashcards
DC MPJE - independent pharmacy jurisprudence foundations · Build recall with a focused review session.
20 cards. Read the term and the definition here. The deck at the top of this page is optional.
- Corresponding responsibility
- The pharmacist's federal responsibility, shared with the prescriber, to assess whether a controlled prescription serves a legitimate medical purpose.
- DEA registration
- Federal registration authorizing specified controlled-substance activities, subject to its scope and other applicable legal authority.
- NPI
- A provider identifier used in standard health transactions, which does not itself grant controlled-substance prescribing authority.
- Refill
- A subsequent dispensing pursuant to remaining prescription authorization, distinct from the original fill or a partial quantity.
- Partial fill
- Dispensing less than the full prescribed quantity under a legally applicable pathway without increasing the total authorization.
- Emergency oral prescription
- A limited federal Schedule II exception with emergency-specific quantity, verification, documentation, and follow-up requirements.
- Biennial inventory
- The required periodic controlled-stock inventory conducted at least every two years following the applicable initial inventory.
- Initial inventory
- The controlled-stock record at the beginning of regulated activity, including a record when no stock is on hand.
- Misbranding
- A legal product category that includes false or misleading labeling, rather than simply describing poor manufacturing conditions.
- Adulteration
- A legal product category covering specified quality or manufacturing defects, which may coexist with other regulatory violations.
- ANDA
- An abbreviated drug application establishing applicable generic approval requirements rather than independently authorizing every local substitution.
- REMS
- An FDA-required product-specific risk-management strategy intended to ensure a medication's benefits outweigh its known serious risks.
- Collaborative practice agreement
- A defined professional agreement specifying authorized drug-therapy activities, related conditions, and monitoring rather than unlimited independent prescribing.
- Generic substitution
- Supplying a qualifying generically equivalent product under the applicable prescriber, purchaser, product, and local statutory conditions.
- Therapeutic interchange
- Replacing a prescribed therapy through the applicable authorization and consent process, distinct from ordinary generic-product substitution.
- Biological-product communication
- The District statutory notice identifying the biological product actually dispensed, including product name and manufacturer when required.
- PDMP registration
- Enrollment required of specified practitioners and dispensers, separate from the duties to report dispensing and query patient history.
- PDMP query
- An authorized examination of prescription-monitoring information, with statutory triggers and exceptions distinct from reporting requirements.
- PHI
- Individually identifiable protected health information subject to applicable HIPAA privacy requirements, rather than all health-related facts.
- Disclosure accounting
- A patient right to specified disclosure information over the applicable period, subject to exceptions including many treatment disclosures.